1. Home
  2. MOVE vs LYEL Comparison

MOVE vs LYEL Comparison

Compare MOVE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Movano Inc.

MOVE

Movano Inc.

N/A

Current Price

$8.63

Market Cap

297.4M

Sector

Health Care

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$14.68

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MOVE
LYEL
Founded
2018
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.4M
320.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MOVE
LYEL
Price
$8.63
$14.68
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
265.8K
165.0K
Earning Date
04-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$433,000.00
$36,000.00
Revenue This Year
$1,460.71
N/A
Revenue Next Year
$96.77
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$10.56
52 Week High
$34.87
$45.00

Technical Indicators

Market Signals
Indicator
MOVE
LYEL
Relative Strength Index (RSI) 31.84 53.52
Support Level $6.80 $11.87
Resistance Level $9.57 $15.63
Average True Range (ATR) 1.25 1.14
MACD -0.08 0.15
Stochastic Oscillator 1.57 40.25

Price Performance

Historical Comparison
MOVE
LYEL

About MOVE Movano Inc.

Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: